Monoclonal antibody targeting of ovarian carcinoma

Oncology

Volumn 55, Issue 5, 1998, Pages 435-446

  Kosmas, Christos ^a,b   Kalofonos, Haralambos P ^a   Hird, Victoria ^a   Epenetos, Agamemnon A ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b NONE   (Greece)

Author keywords

Immunoscintigraphy; Monoclonal antibodies; Ovarian cancer

Indexed keywords

ALKALINE PHOSPHATASE PLACENTA ISOENZYME; CHELATING AGENT; INDIUM 111; IODINE 123; MACROCYCLIC COMPOUND; MONOCLONAL ANTIBODY;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CLINICAL ARTICLE; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LAPAROSCOPY; LAPAROTOMY; OVARY CANCER; PILOT STUDY; PRIORITY JOURNAL;

EID: 0031858457     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000011892     Document Type: Article

References (48)

1. Young RC, Perez CA, Hoskins WJ: Cancer of the ovary, in De Vita VT, Hellman S, Rosenberg SA (eds): Principles and Practice of Oncology, ed 4. Philadelphia, Lippincott, 1993, pp 1226-1263.
2. Marsoni S, Torri V, Valsecchi MG, Belloni C, Bianchi V, Bolis G, Bonazzi C, Colombo N, Epis A, Favalli G, Gambino A, Landoni F, Maggi R, Pecorelli S, Presti S, Vassena L, Zanaboni F, Magnioni C: Prognostic factors in advanced epithelial ovarian cancer. Br J Cancer 1990;62:444-450.
3. Ozols RF: Treatment of ovarian cancer. Semin Oncol 1994;21(suppl 2):1-9.
4. Howell SB, Kirmani S, McClay EF, Kim S, Braly P, Plaxe S: Intraperitoneal cisplatinbased chemotherapy for ovarian carcinoma. Semin Oncol 1991;18(suppl 3):5-10.
5. Goldie JH, Goldman AJ: A mathematical model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 1979;63:1727-1733.
6. Rustin GJS, Gennings JN, Nelstrop AE, Covarrubias H, Lambert HE, Bagshawe KD: Use of CA-125 to predict survival of patients with ovarian carcinoma. J Clin Oncol 1989;7:1667-1671.
7. Goldenberg DM: Monoclonal antibodies in cancer detection and therapy. Am J Med 1983; 94:297-312.
8. Siccardi AG, Buraggi GL, Callegaro L, Collela AC, De Filippi PG, Galli G, Mariani G, Masi R, Palumbo G, Riva P, Salvatore M, Scasselati GA, Scheidhauer K, Turco GL, Zaniol P, Benini S, Deleide G, Gasparini M, Lastoria S, Mansi L, Paganelli G, Salvischiani E, Seregni E, Viale G, Natali P: Immunoscintigraphy of adenocarcinomas by means of radiolabeled F(ab′)2 fragments of an anti-carcinoembryonic antigen monoclonal antibody: Multicenter study. Cancer Res 1989;49:3095-3103.
9. Beatty JD, Williams LE, Yamauchi D, Morton BA, Hill LR, Beatty BG, Paxton RJ, Merchant B, Shively JE: Presurgical imaging with indium-labeled anti-carcinoembryonic antigen for colon cancer staging. Cancer Res 1990;50: 922-926.
10. Abdel-Nabi H, Doerr RJ, Chan HW, Parrel E, Evans NH, Spaulding MB, Schweighardt S, Merchant EB: Safety and role of repeated administration of In-111 labeled anti-carcinoembryonic antigen monoclonal antibody ZCE 025 in the post-operative follow-up of colorectal carcinoma patients. J Nucl Med 1992;33:14-22.
11. Epenetos AA, Britton KE, Mather S, Shepherd J, Granowska M, Taylor-Papadimitriou J, Nimmon CC, Durbin H, Hawkins LR, Malpas JS, Bodmer WF: Targeting of 1231-labelled tumour associated monoclonal antibodies to ovarian, breast and gastrointestinal tumours. Lancet 1982;ii:999-1003.
12. Pateisky N, Philip K, Skodler WD, Czerwenka K, Hamilton G, Burchell J: Radioimmunodetection in patients with suspected ovarian cancer. J Nucl Med 1985;26:1369-1376.
13. Granowska M, Britton KE, Shepherd JH, Nimmon CC, Mather S, Ward B: A prospective study of 123-I-labeled monoclonal antibody imaging ovarian cancer. J Clin Oncol 1986;4: 730-736.
14. Epenetos AA, Munro AJ, Stewart R, Rampling R, Lambert HE, McKenzie CG, Soutter P, Rahemtula A, Hooker G, Sivolapenko GB, Snook D, Courtenay-Luck NS, Dhokia B, Krausz T, Taylor-Papadimitriou J, Durbin H, Bodmer WF: Antibody-guided irradiation of advanced ovarian cancer with intraperitoneally administered radiolabeled monoclonal antibodies. J Clin Oncol 1987;5:1890-1899.
15. Courtenay-Luck NS, Epenetos AA, Morre R, Larche M, Pectasides D, Dhokia B, Ritter MA: Development of primary and secondary immune responses to mouse monoclonal anti-bodies used in the diagnosis and therapy of malignant neoplasms. Cancer Res 1986;46: 6489.
16. Reichmann L, Clark M, Waldmann H, et al: Reshaping human antibodies for therapy. Nature 1988;332:323-327.
17. Verhoeyen M, Broderick L, Eida S, Badley RA: Reshaped human anti-PLAP antibodies; in Epenetos AA (ed): Monoclonal Antibodies, ed 1. London, Chapman & Hall, 1991, pp 37-43.
18. 90Y-labeled antibody uptake by human tumor xenografts and the effect of systemic administration of EDTA. Int J Radiat Oncol Biol Phys 1994;28:1257-1265.
19. Meares CF, Moi MK, Diril H, Kukis DL, McCall MJ, Deshpande SV, DeNardo SJ, Snook D, Epenetos AA: Macrocyclic chelates of radiometals for diagnosis and therapy. Br J Cancer 1990;62(suppl X):21-26.
20. Hird V, Maraveyas A, Snook D, Dhokia B, Soutter WP, Meares C, Stewart JSW, Mason P, Lambert HE, Epenetos AA: Adjuvant therapy of ovarian cancer with radioactive monoclonal antibody. Br J Cancer 1993;68:403-406.
21. Burchell J, Durbin H, Taylor-Papadimitriou J: Complexity of expression of antigenic determinants recognized by monoclonal antibodies HMFG1 and HMFG2 in normal and malignant human mammary epithelial cells. J Immunol 1983;131:508-513.
22. Arklie J, Taylor-Papadimitriou J, Bodmer WF, Egan M, Millis R: Differentiation antigens expressed by epithelial cells in the lactating breasts are also detected in breast cancer. Int J Cancer 1981;28:23-29.
23. Travers P, Bodmer WF: Preparation and characterisation of monoclonal antibodies against placental alkaline phosphatase and other human trophoblast associated determinants. Int J Cancer 1984;33:633-641.
24. Durbin H, Tucker DF, Milligan MG, Bobrow LG, Warne PH, Pookim YL, Bodmer WF: Production of monoclonal antibodies to placental alkaline phosphatase: Preliminary characterisation includes identification of one antibody reactive with routinely fixed histological preparations. Int J Cancer 1988(suppl 2):50-58.
25. McLaughlin PJ, Cheng MH, Slade MB, Johnson PM: Expression on cultured human tumour cells of placental trophoblast membrane antigens and placental alkaline phosphatase defined by monoclonal antibodies. Int J Cancer 1982;30:21-26.
26. McLaughlin PJ, Travers P, McDicken IW, Johnson PM: Demonstration of placental and placental-like alkaline phosphatase in non-malignant tumour tissue extracts using monoclonal antibodies in an enzyme immunoassay. Clin Chim Acta 1984;137:341-348.
27. Fraker PJ, Speck JC: Protein and cell membrane iodination with a sparingly soluble chloramine 1,3,4,6-tetrachloro-5,6-diphenyl glycouronil. Biochem Biophys Res Commun 1978;80:949-957.
28. Hnatowich DJ, Childs RL, Lateigne D, Najafi A: The preparation of DTPA-coupled anti-bodies radiolabeled with metalic radionuclides: An improved method. J Immunol Methods 1983;6:147-152.
29. Moi MK, Meares CF, DeNardo SJ: The peptide way to macrocycle bifunctional chelating agents: Synthesis of 2-(p-nitrobenzyl)-1.4,7,10-tetraazacyclododecane-N, N′,N″,N′-tetraacetic acid, and study of its yttrium (III) complex. J Am Chem Soc 1988;110:6266-6267.
30. Meares CF, McCall MJ, Reardan DT, Goodwin DA, Diamanti CI, McTigue M: Conjugation of antibodies with bifunctional chelating agents: Isothiocyanate and bromoacetamide reagents, methods of analysis, and subsequent addition of metal ions. Anal Biochem 1984; 142:68-78.
31. Snook DE, Rowlinson G, Meares C, Epenetos AA: Indium-111-and yttrium-90-labelled macrocyclic chelating agents; in Epenetos AA (ed): Monoclonal Antibodies, ed 1. London, Chapman * Hall, 1991, pp 157-166.
32. Graham RC, Karnovsky MJ: The early stage of absorption of injected horseradish peroxidase in the proximal tubules of the mouse kidney: Ultrastructural histochemistry by a new technique. J Histochem Cytochem 1966;14:291-302.
33. 2 fragments. Cancer Res 1988;48:1877-1884.
34. Kosmas C, Snook DE, Gooden CS, Courtenay-Luck NS, McCall MJ, Meares CF, Epenetos AA: Development of humoral immune responses against a macrocyclic chelating agent (DOTA) in cancer patients receiving radioimmunoconjugates for imaging and therapy. Cancer Res 1992;52:904-911.
35. Moffat FL, Vargas-Cuba RD, Serafini AN, Casillas VJ, Morillo G, Benedetto P, Robinson DS, Ardalan B, Manten HD, Kimberley CC, Carido J, Ketcham AS, Pinsky CM: Radio-immunodetection of colorectal carcinoma using technetium-99m-labeled Fab′ fragments of IMMU-4 anticarcinoembryonic antigen monoclonal antibody. Cancer 1994;73(suppl 3):836-845.
36. Kalofonos HP, Sackier JM, Hatzistylianou M, Pervez S, Taylor-Papadimitriou J, Waxman JH, Lavender JP, Wood C, Epenetos AA: Kinetics, quantitative analysis and radioimmunolocalization using indium-111-HMFG1 monoclonal antibody in patients with breast cancer. Br J Cancer 1989;59:939-942.
37. Yokota T, Milenic DE, Whitlow M, Schlom J: Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res 1992;52:3402-3408.
38. Chester KA, Begent RHJ, Robson L, Keep P, Pedley RB, Boden JA, Boxer G, Green A, Winter G, Crochet O, Hawkins RE: Phage libraries for generation of clinically useful antibodies. Lancet 1994;343:455-456.
39. Delgado C, Pedley RB, Herraez A, Boden R, Boden JA, Keep PA, Chester KA, Fisher D, Begent RHJ, Francis GE: Enhanced tumour specificity of an anti-carcinoembryonic antigen Fab′ fragment by poly(ethyleneglycol) (PEG) modification. Br J Cancer 1996;73:175-182.
40. Kalofonos HP, Kosmas C, Hird V, Snook DE, Epenetos AA: Targeting of tumours with murine and reshaped human monoclonal anti-bodies against placental alkaline phosphatase: Immunolocalisation, pharmacokinetics and immune response. Eur J Cancer 1994;30A: 1842-1850.
41. Hale G, Dyer MJS, Clark MR, Philips JM, Marcus R, Riechmann L, Winter G: Remission induction in non-Hodgkin's lymphoma with reshaped human monoclonal antibody CAM-PATH-1. Lancet 1988;ii:1394-1399.
42. LoBuglio AF, Wheeler RH, Trang J, Haynes A, Rogers K, Harvey EB, Sun L, Ghrayeb J, Khazaeli MB: Mouse/human chimeric monoclonal antibody in man: Kinetics and immune response. Proc Natl Acad Sci USA 1989;86: 4220-4224.
43. Steis RG, Carrasquillo JA, McCabe R, Bookman MA, Reynolds JC, Larson SM, Smith JW, Clark JW, Dailey V, Del Vecchio S, Shuke N, Pinsky CM, Urba WJ, Haspel M, Perentesis P, Paris B, Longo DL, Hanna MG Jr: Toxicity, immunogenicity, and tumor radioimmunodetecting ability of two human monoclonal anti-bodies in patients with metastatic colorectal carcinoma. J Clin Oncol 1990;8:476-490.
44. Chester KA, Robson L, Keep PA, Pedley RB, Boden JA, Boxer GM, Hawkins RE, Begent RHJ: Production and tumour-binding characterization of a chimeric anti-CEA Fab″ expressed in Escherichia coli. Int J Cancer 1994; 57:67-72.
45. Verhaar MJ, Chester KA, Keep PA, Robson L, Pedley RB, Boden JA, Hawkins RE, Begent RHJ: A single chain Fv derived from a filamentous phage library has distinct tumor targeting advantages over one derived from a hybridoma. Int J Cancer 1995;61:497-501.
46. Kosmas C, Maraveyas A, Gooden CS, Snook D, Epenetos AA: Anti-chelate antibodies after intraperitoneal yttrium-90-labeled monoclonal antibody immunoconjugates for ovarian cancer therapy. J Nucl Med 1995;36:746-753.
47. Kosmas C, Epenetos AA, Courtenay-Luck NS: Activation of cellular immunity after intracavitary monoclonal antibody therapy of ovarian cancer. Cancer 1994;73:3000-3010.
48. Lederman JA, Begent RHJ, Bagshawe KD, Riggs SJ, Searle F, Glaser MG, Green AJ, Dale RG: Repeated anti-tumour antibody therapy in man with suppression of the host response by cyclosporin A. Br J Cancer 1988;58:654-657.